drowsiness

/Tag: drowsiness

Las Vegas CES2019 Highlights

The Consumer Electronics Show (CES2019) dazzled participants once again with glimpses of technologies and products on the horizon for the future.  With over 180,000 attendees from 150 different countries, circulating over 11 venues throughout Las Vegas. Optalert’s key conversations at this year’s event included autonomous vehicles, enhanced ‘early warning’ drowsiness and distraction features, and AI assisting in remote healthcare technology. Optalert’s Chief Technical Officer Simon Block, shares some of his top highlights for the show:    1. Automotive Innovation Intelligent cars dominated the conversation in the automotive market, with seamless connectivity critical [...]

By |2019-01-17T14:05:06+00:00January 17th, 2019|Automotive, Pharmaceutical|

Introducing the BlinQ system by Optalert

Optalert is pleased to introduce the BlinQ system for the measurement of drowsiness or wakefulness in clinical trials. Optalert uses advanced patented algorithms to determine the exact drowsiness or wakefulness of a subject.  By applying Artificial Intelligence techniques and machine learning Optalert has been able to objectively quantify drowsiness or wakefulness.  Utilising the Johns Drowsiness Scale (JDS), Optalert's future-proofed approach can advance clinical drug trial timelines and deliver new therapies to market faster. Current methodologies for measuring drowsiness or wakefulness are used across a wide range of clinical drug trials including anti-depressants, shift-work disorder, narcolepsy [...]

By |2018-12-17T15:50:16+00:00December 17th, 2018|Pharmaceutical|

Challenges of pharmaceutical companies

Pharmaceutical companies face many challenges, with hundreds of new drugs required to transition through clinical trial phases, regulatory processes and to market, more quickly and more efficiently. The Centre for the Study of Drug Development (CSDD) estimates the cost of developing a prescription drug that gains market approval at $2.6 billion. Even more remarkable is that 90% of medicines that start being tested in people don’t reach the market because they are unsafe or ineffective. “May cause drowsiness” This is a common warning label on [...]

By |2018-11-08T10:52:12+00:00November 2nd, 2018|Pharmaceutical|
Translate » Language